Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Hepatology (Baltimore, Md.) - 1 Sept 2010

Muir Andrew J, Shiffman Mitchell L, Zaman Atif, Yoffe Boris, de la Torre Andrew, Flamm Steven, Gordon Stuart C, Marotta Paul, Vierling John M, Lopez-Talavera Juan Carlos, Byrnes-Blake Kelly, Fontana David, Freeman Jeremy, Gray Todd, Hausman Diana, Hunder Naomi N, Lawitz Eric

Abstract excerpt

UNLABELLED: Interferon lambda 1 (IFN-lambda1) is a type III IFN that produces intracellular responses similar to those of IFN-alpha but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile. This was an open-label three-part study of patients with chronic hepatitis C virus (HCV) genotype 1 infection. Part 1 evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Fatigue

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Nausea

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 20564352
DOI: 10.1002/hep.23743

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.PMID 20564352Read ↗

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.Semantic proximity Read ↗

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.Semantic proximity Read ↗

Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.Semantic proximity Read ↗

Pilot study of interferon gamma for chronic hepatitis C.Semantic proximity Read ↗

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.Semantic proximity Read ↗

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.Semantic proximity Read ↗

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.Semantic proximity Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.Semantic proximity Read ↗

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.Semantic proximity Read ↗

Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.Semantic proximity Read ↗

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.